Cyclerion enters licensing agreement with MIT, announces strategic relaunch

Cyclerion Therapeutics (CYCN) announced that it has entered into a licensing agreement with the Massachusetts Institute of Technology, securing the intellectual property that will serve as the cornerstone of its strategic relaunch. This agreement marks a milestone in Cyclerion’s transformation into a new company focused on delivering therapies for neuropsychiatric conditions with large unmet needs, beginning with treatment-resistant depression. Cyclerion’s lead program leverages common anesthetic agents and a proprietary, tech-driven system to resynchronize communication between key brain regions and restore functional connectivity in patients with TRD. A Phase 2 proof-of-concept trial for its lead program is expected to initiate in 2026, with an initial data set anticipated in 2027. In addition to its lead program, Cyclerion is actively exploring expansion into other neuropsychiatric diseases.